Localized scleroderma

  title={Localized scleroderma},
  author={Ronald M. Laxer and Francesco Zulian},
  journal={Current Opinion in Rheumatology},
Purpose of reviewLocalized scleroderma, also known as morphoea, has a variety of clinical manifestations that can include systemic involvement. Early recognition, diagnosis and treatment may improve the long-term outcome. Recent findingsA large multicentre study coordinated by the Pediatric Rheumatology European Society has yielded important information on the epidemiology and clinical manifestations of juvenile localized scleroderma, especially as it pertains to systemic manifestations… 
Overview of Juvenile localized scleroderma and its management
JLS is associated with a risk for disabling and disfiguring morbidity for the growing child and identifying active disease is important for guiding treatment, but often difficult because of the paucity of markers and lack of a universal skin activity feature.
Scleroderma in children.
  • F. Zulian
  • Medicine
    Best practice & research. Clinical rheumatology
  • 2017
Localized Scleroderma
Morphea (localized scleroderma) is an autoimmune disease characterized by sclerosis of the skin and, in some cases, subcutaneous tissue. It occurs in children and adults. It is distinct from systemic
Treatment in Juvenile Scleroderma
The recent recommendations for juvenile scleroderma represent an important instrument to standardize the treatment approach, confirm the role of methotrexate, and open new windows for effective experimental treatments, such as mycophenolate mofetil and biological agents, for severe or refractory cases.
Chapter 2 Localized Scleroderma
Morphea (localized scleroderma) is an autoimmune disease characterized by sclerosis of the skin and, in some cases, subcutaneous tissue. It occurs in children and adults. It is distinct from systemic
Case Report: Late onset of generalized isomorphic morphea in a postmenopausal woman
A 66-year-old Caucasian Peruvian female patient, who was previously a nurse, presented with a prior history of 4 years of indurated dermal plaque lesions with constant progression with progressive clinical improvement, and started topical treatment with methoxsalen and phototherapy.
Upcoming treatments for morphea
Different classes of therapeutics, including antifibrotic, anti‐inflammatory, cellular and gene therapy, and antisenolytic approaches, and how these target different aspects of disease pathogenesis are focused on.
New developments in juvenile systemic and localized scleroderma.
  • I. Foeldvari
  • Medicine
    Rheumatic diseases clinics of North America
  • 2013


Congenital localized scleroderma.
Localized scleroderma in childhood is not just a skin disease.
In patients with extracutaneous involvement, the prevalence of antinuclear antibodies and rheumatoid factor was significantly higher than that among patients with only skin involvement, however, Scl-70 and anticentromere, markers of SSc, were not significantly increased.
Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study.
The insidious onset of the disease, the delay in diagnosis, the recognition of mixed subtype and the better definition of the other subtypes should influence the efforts in educating trainees and practitioners and help in developing a comprehensive classification system for this syndrome.
Linear Scleroderma en coup de sabre With Associated Neurologic Abnormalities
These patients' cases highlight the underrecognized relationship between neurologic complications and linear scleroderma en coup de sabre and illustrate the importance of a thorough skin examination in patients with unexplained neurologic disease.
Internal Involvement in Localized Scleroderma
After a median follow-up of 48 months, such involvement did not impair the prognosis and the mildness of these visceral abnormalities suggests that they do not justify routine detection in asymptomatic patients.
Unilateral generalized morphea is a rare variant of localized scleroderma.
Four young patients exhibiting a similar subtype of LS in childhood are described and UGM is introduced as an extreme variant of the linear form ofLS in childhood, which usually occurs in pediatric patients.
Treatment of pediatric localized scleroderma with methotrexate.
MTX appears to be a safe and effective therapy for children with localized scleroderma who failed topical therapy and were subsequently treated with MTX with or without oral corticosteroids.
Combining PUVA therapy with systemic immunosuppression to treat progressive diffuse morphoea
The case of a patient treated initially with cyclosporin and PUVA and subsequently with MMF andPUVA, with considerable improvement in his condition is presented.
Localized scleroderma: response to occlusive treatment with tacrolimus ointment
Oral psoralen photochemotherapy has been used in five reported cases of children with diffuse cutaneous mastocytosis, with very encouraging results, and suggests that the use of topical Psoralen is more useful than has previously been reported.